Short answer
Voyager Therapeutics, Inc. (VYGR) filed an 8-K current report with the SEC on April 21, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CFO Nathan Jorgensen resigns effective May 8, 2026 to pursue a new opportunity.
Voyager Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CFO Nathan Jorgensen resigns effective May 8, 2026 to pursue a new opportunity
- Resignation explicitly unrelated to disagreement, reducing immediate governance concern
- Robin Swartz becomes principal financial officer and treasurer, adding finance responsibilities to her COO and CBO roles
- Amy Quinlan becomes principal accounting officer, providing dedicated accounting leadership
- Finance transition relies on internal executives with prior finance, auditing, and financial planning experience
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Voyager Therapeutics, Inc. 8-K filings
Get the next VYGR 8-K as it lands
Follow VYGR for push alerts, or ask the research agent what this filing means.